Displaying 1 - 6 of 6
| Active Ingredient | CHOLESTYRAMINE |
| Therapeutic Class | BILE ACID SEQUESTRANTS |
| Indications |
An effective bile acid sequesterant for use in treating type IIa hypercholesterolemia. The drug has also been used for diarrhea associated with Crohn's disease, and for pruritus associated with bi More ... |
| Caution | Constipation, abdominal discomfort, nausea, flatulence, vomiting, diarrhoea, heartburn, anorexia and indigestion. Deficiency of fat soluble vitamins may occur. |
| Dose Range | Adult and children over 12 years: Recommended starting dose is 4g once or twice daily . Maintenance dose: 8-16g daily in two divided doses. Maximum recommended daily dose: 36 grams daily in 2-4 diveded doses. Pediatric 6-12 years: 4g once to 3 ti |
| Drug Interactions | |
| Pregnancy | Since cholestyramine resin is not absorbed systemically, the drug is not expecte More ... |
| Breast Feeding |
| Active Ingredient | EZETIMIBE |
| Therapeutic Class | CHOLESTEROL ABSORPTION INHIBITORS |
| Indications | An adjunct to dietary measures and statin treatment.Reduction of total cholesterol, low-density lipoprotein (LDL)-cholesterol, and apolipoprotein B in the management of hyperlipidaemias. |
| Caution | Headache, abdominal pain, and diarrhoea. Contraindicated in patients with active liver disease or unexplained, persistent increases in serum aminotransferase (transaminase) concentrations. |
| Dose Range | 10mg once daily . Must be used in combination with a statin. |
| Drug Interactions | |
| Pregnancy | Use during pregnancy only if potential benefit to the mother outweighs the possi More ... |
| Breast Feeding |
| Active Ingredient | FENOFIBRATE |
| Therapeutic Class | FIBRIC ACID DERIVATIVES |
| Indications |
Used to reduce low-density lipoprotein (LDL)-cholesterol, total cholesterol, triglycerides, and apolipop rotein B, and to increase high-density lipoprotein (HDL)-cholesterol, in the management of Hy More ... |
| Caution | Liver function test should be carried out every 3 months.Serious muscle toxicity, including myopathy and rhabdomyolysis, has been reported in patients receiving fibric acid derivatives. Risk appears t More ... |
| Dose Range |
Adult: 67 mg three times daily or 200 mg once daily . Pediatric (4-15 years): 1 cap sule/20mg daily . |
| Drug Interactions | |
| Pregnancy | Fenofibrate is not recommended during pregnancy. |
| Breast Feeding | Fenofibrate is not recommended for lactating women. |
| Active Ingredient | GEMFIBROZIL |
| Therapeutic Class | FIBRIC ACID DERIVATIVES |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ATORVASTATIN |
| Therapeutic Class | HMG-CoA REDUCTASE INHIBITORS |
| Indications |
Effective in the treatment of hyper-cholesterolemia and hypertrigly ceridemia. |
| Caution | Headache, diarrhoea, flatulence and mild elevations in liverenzymes. The risk of myopathy and/or rhabdomyolysis is increased when atorvastatin is taken concomitantly with cyclosporine, gemfibrozil, More ... |
| Dose Range |
Adult: Initial dose 10-20mg once daily. The dose may be adjusted at intervals of at least 4 weeks up to a maximum of 80 mg daily . See BDS supply protocols pg. 6. |
| Drug Interactions | |
| Pregnancy | Statins should be avoided in pregnancy (discontinue 3 months before attempting t More ... |
| Breast Feeding | Avoid use of atorvastatin in lactating women. |
| Active Ingredient | ROSUVASTATIN |
| Therapeutic Class | HMG-CoA REDUCTASE INHIBITORS |
| Indications | Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia)’ mixed dyslipidaemia (type Iib), or homozygous familial hypercholesterolaemia in patients who have n More ... |
| Caution | Headache, asthenia, upper respiratory infections, gastrointestinal symptoms, and myalgia have been reported; myopathy has occurred rarely . |
| Dose Range | Adult: 5-20mg once daily . Doses may be titrated to 40mg per day in those who do not meet their lipid lowering goals on 20mg per day. Doses to be increased at intervals of at least 4 weeks. See BDS supply protocols pg. 6. |
| Drug Interactions | |
| Pregnancy | Statins should be avoided in pregnancy (discontinue 3 months before attempting t More ... |
| Breast Feeding | Avoid use of rosuvastatin in lactating women. |